Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022 7:30 AM EDTFirst quarter 2022 results reflect strong CAPLYTA® (lumateperone) launch in bipolar depression
 First quarter 2022 CAPLYTA new and total prescriptions increased 63% and 45%, respectively, versus the fourth quarter 2021   First quarter 2022 CAPLYTA new and total prescriptions increased 154% and 134%, respectively, versus the same period in 2021   New-to-brand CAPLYTA prescriptions, representing new patient starts, have increased approximately 300% following bipolar depression... More